Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy.J Am Coll Cardiol. 2003; 41: 916-924
- Prognostic usefulness of serial C-reactive protein measurements in ST-elevation acute myocardial infarction.Am J Cardiol. 2013; 111: 26-30
- Prognostic significance of the centers for disease control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.Circulation. 2007; 115: 1528-1536
- C-reactive protein in atherosclerosis: a causal factor?.Cardiovasc Res. 2006; 71: 30-39
- C-reactive protein and angiographic coronary artery disease: Independent and additive predictors of risk in subjects with angina.J Am Coll Cardiol. 2002; 39: 632-637
- Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study.Circulation. 2006; 113: 38-43
- C-reactive protein elevation and disease activity in patients with coronary artery disease.Eur Heart J. 2004; 25: 401-408
- Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) study.JACC Cardiovasc Imaging. 2011; 4: 894-901
- In-vivo detection of high risk coronary plaques by intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study.Eur Heart J. 2014; 35: 639-647
- A prospective natural-history study of coronary atherosclerosis.N Engl J Med. 2011; 364: 226-235
- Tissue characterisation using intravascular radiofrequency data analysis: recommendations for acquisition, analysis, interpretation and reporting.Eurointervention. 2009; 5: 177-189
- Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation.Eurointervention. 2007; 3: 113-120
- In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis.J Am Coll Cardiol. 2005; 46: 2038-2042
- Relation of genetic profile and novel circulating biomarkers with coronary plaque phenotype as determined by intravascular ultrasound: rationale and design of the ATHEROREMO-IVUS study.EuroIntervention. 2013; (pii:20130113–01. http://dx.doi.org/10.4244/EIJY13M08_01 [Epub ahead of print].)
- Task force on the management of chest pain.Eur Heart J. 2002; 23: 1153-1176
- Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association.Circulation. 2003; 107: 499-511
- Genetically elevated C-reactive protein and ischemic vascular disease.N Engl J Med. 2008; 359: 1897-1908
- Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina.Atherosclerosis. 2008; 196: 779-785
- Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability.Circulation. 1999; 99: 855-860
- Association between high-sensitivity C-reactive protein and coronary plaque subtypes assessed by 64-slice coronary computed tomography angiography in an asymptomatic population.Circ Cardiovasc Imaging. 2011; 4: 201-209
- Elevated C-reactive protein in atherosclerosis—chicken or egg?.N Engl J Med. 2008; 359: 1953-1955
- Inflammation in atherosclerosis.Nature. 2002; 420: 868-874
- Triggering of acute myocardial infarction: beyond the vulnerable plaque.Heart. 2010; 96: 1247-1251
- Is there a vulnerable plaque?.Circulation. 2003; 107: 2068-2071
- Imaging of coronary atherosclerosis: intravascular ultrasound.Eur Heart J. 2010; 31: 2456-2469
Cheng and Oemrawsingh contributed equally to this work.
The ATHEROREMO-IVUS study was funded by the European Commission, Seventh Framework Program, Brussels, Belgium, theme FP7-HEALTH-2007-2.4.2-1. JMC and RMO are supported by grant numbers NHS2009B091 and NHS2007B012, respectively, from The Netherlands Heart Foundation, Den Haag, The Netherlands.
See page 1503 for disclosure information.